MAY 22, 2021 8:28 AM PDT

FDA Approves Trials for Ketamine to Treat Parkinson's

WRITTEN BY: Annie Lennon

The US FDA has approved PharmaTher’s Investigational New Drug application to begin Phase 2 clinical trials for ketamine to treat levodopa-induced dyskinesia in patients with Parkinson’s disease. 

Levodopa is an amino acid precursor of dopamine and is commonly used alongside carbidopa, an inhibitor of L-amino acid decarboxylase, to treat Parkinson's disease symptoms including tremor, muscle stiffness and slowness of movement. 

Dyskinesia, characterized by rapid, involuntary and uncontrollable movements distinct from the typical tremors associated with Parkinson's, is a side effect of long-term levodopa use. Around half of the patients treated with the drug develop the condition within five years of initial treatment, and almost all patients develop it within ten years. 

While dyskinesia can be localized to one part of the body, it can also spread to other areas. It can also affect speech, the respiratory tract, and the eye muscles in rare cases. 

The underlying cause of dyskinesia from Levodopa is not currently known. However, it may be the result of fluctuations in dopamine caused by the drug, alongside a loss of dopaminergic neurons seen in those with Parkinson's. 

In a retrospective analysis of patients with Parkinson’s disease, researchers found that those treated with ketamine for pain relief experienced an improvement in dyskinesia symptoms. Other studies have found that ketamine may also be able to treat pain and depression, other symptoms that are frequently found in those with Parkinson’s. 

Having now received approval to commence Phase 2 trials investigating the effects of ketamine on Levodopa-induced dyskinesia, the researchers at PharmaTher plan on recruiting up to 36 subjects across eight clinical sites in the US. They will assess the patients according to changes in the Unified Dyskinesia Rating Scale over 8 weeks. They will also monitor total daily ‘off times’, periods when Parkinson’s symptoms return despite the use of medication, from 24-hour diaries. 

 

Sources: American Parkinson Disease AssociationParkinson's News TodayGlobal Newswire

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 01, 2022
Cannabis Sciences
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London found ...
NOV 29, 2022
Drug Discovery & Development
75g Kale Per Day Could Keep Bone Fractures Away
75g Kale Per Day Could Keep Bone Fractures Away
Vitamin K1- a nutrient found in leafy greens like kale, cabbage, and spinach- may help reduce bone fracture risk in elde ...
DEC 02, 2022
Neuroscience
Scientists Identify Distinct Brain Networks Associated with Risk and Resilience in Depression
Scientists Identify Distinct Brain Networks Associated with Risk and Resilience in Depression
A study published in Brain found a link between the location of brain injury to levels of depression in patients followi ...
JAN 05, 2023
Health & Medicine
A noninvasive sleep sensor that could prevent opioid overdose in recovering patients
A noninvasive sleep sensor that could prevent opioid overdose in recovering patients
Opioid Use Disorder (OUD) is a chronic condition of opioid use that results in significant distress, dependence, relapse ...
JAN 31, 2023
Drug Discovery & Development
A Whipped Jet Aerosol Sprayer that could Change Drug Discovery
A Whipped Jet Aerosol Sprayer that could Change Drug Discovery
A whipped jet aerosol sprayer that has the potential to revolutionize everything from the pharmaceutical to automobile i ...
JAN 30, 2023
Cancer
Kiwi Juice Provides Therapeutic Benefit in Lung Cancer Model
Kiwi Juice Provides Therapeutic Benefit in Lung Cancer Model
Actinidia arguta, commonly known as the hardy kiwi or kiwi berry, looks like a smaller, hairless version of the Actinidi ...
Loading Comments...